The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

In other words there is a correct inhaler technique ... College of General Practitioners respiratory clinical lead. He speaks regularly on asthma and COPD issues.

In today’s fast-paced world, respiratory health has become a significant concern for many individuals. Conditions such as ...

“This could influence treatment decisions and improve respiratory health in this high-risk population.” “GLP-1 medications might help lower COPD exacerbation risk by reducing systemic ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

Chronic conditions such as asthma, COPD, and other breathing ... For many individuals with chronic respiratory conditions, the reliance on inhalers and steroids can be a frustrating and limiting ...

including heart disease and lung cancer. Make sure to keep regular appointments with your healthcare team to discuss your COPD, any medications you may take or want to know about, and other steps ...

In addition, Pneuma has programs in developing treatments for conditions like chronic obstructive pulmonary disease (COPD ... s inhaled therapeutics have broad potential in treating other lung ...